Market
Primary challenge in adoption of new HIV prevention injections by end of 2025?
2
Resolution / Starting Odds
Cost • 25%
Distribution • 25%
Adherence • 25%
Regulatory Approval • 25%
Reports from global health organizations and research studies
Story
New HIV Prevention Injections Offer Six Months Protection; 100% Effective, Gilead to Sell Generics Ahead of World AIDS Day
Dec 1, 2024, 04:00 PM
Recent advancements in HIV prevention include long-acting injections that provide protection for up to six months per shot. As World AIDS Day approaches, experts are evaluating the implications of these new tools in combating HIV. A study has shown that a twice-yearly injection was 100% effective in preventing HIV infections among women and nearly as effective in men. Pharmaceutical company Gilead has announced plans to sell affordable generic versions of the medication in 120 countries with high rates of HIV. Despite these advancements, experts emphasize the importance of equitable access and addressing adherence challenges to maximize the impact of HIV prevention efforts.
View original story
Similar markets
Cost • 25%
Manufacturing capacity • 25%
Public awareness • 25%
Regulatory approvals • 25%
Neither dominates • 25%
Both equally • 25%
Lenacapavir • 25%
Cabotegravir • 25%
Cost • 25%
Adherence • 25%
Regulatory approval • 25%
Distribution • 25%
Approved in UK only • 25%
Not approved in any major market • 25%
Approved in UK and EU • 25%
Approved in UK, EU, and USA • 25%
Ethical Concerns • 25%
Informed Consent Challenges • 25%
Other • 25%
Logistical Issues • 25%
Ineffective Policies • 25%
Lack of Funding • 25%
Access to Medication • 25%
Stigma and Discrimination • 25%
USA • 25%
UK • 25%
Other • 25%
South Africa • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%